OBJECTIVE: To determine whether measuring monoclonal bands (M component) in serum should be part of the investigation of patients referred to osteoporosis clinics. DESIGN: Retrospective, cross sectional, observational study. SETTING: Referral centre for osteoporosis in a university hospital, Denmark. PARTICIPANTS: 799 people (685 women) aged 19 to 94 years newly referred with suspected osteoporosis. MAIN OUTCOME MEASURES: Proportion of patients fulfilling the Nordic Myeloma Study Group definition for target condition and proportion of patients with other important haematological conditions. RESULTS: 4.9% (18 of 366) of patients with osteoporosis and 2.2% (9 of 408) of patients without osteoporosis had M component in serum (chi2 = 3.66, P = 0.04). Multiple myeloma was diagnosed in three patients with osteoporosis (absolute risk 0.8%, 95% confidence interval 0.11% to 1.7%). The relative risk of multiple myeloma in patients presenting with osteoporosis was 75 (10 to 160). As a diagnostic test for multiple myeloma in patients with osteoporosis, M component in serum had a specificity of 95.0% and a positive predictive value of 17.6%. 122 blood electrophoreses were carried out for each case of multiple myeloma diagnosed. All patients with multiple myeloma had a history of fragility fractures. If lymphoma was included as a target condition, the specificity increased to 95.3% and the positive predictive value increased to 23.5%. Monoclonal gammopathy of undetermined significance was diagnosed in 13 (3.6%) participants with osteoporosis and in eight (2.0%) participants with normal bone mineral density or osteopenia. CONCLUSIONS: Patients presenting with osteoporosis should be tested for M component in serum, as 1 in 20 patients with newly diagnosed osteoporosis had multiple myeloma or monoclonal gammopathy of undetermined significance.
OBJECTIVE: To determine whether measuring monoclonal bands (M component) in serum should be part of the investigation of patients referred to osteoporosis clinics. DESIGN: Retrospective, cross sectional, observational study. SETTING: Referral centre for osteoporosis in a university hospital, Denmark. PARTICIPANTS: 799 people (685 women) aged 19 to 94 years newly referred with suspected osteoporosis. MAIN OUTCOME MEASURES: Proportion of patients fulfilling the Nordic Myeloma Study Group definition for target condition and proportion of patients with other important haematological conditions. RESULTS: 4.9% (18 of 366) of patients with osteoporosis and 2.2% (9 of 408) of patients without osteoporosis had M component in serum (chi2 = 3.66, P = 0.04). Multiple myeloma was diagnosed in three patients with osteoporosis (absolute risk 0.8%, 95% confidence interval 0.11% to 1.7%). The relative risk of multiple myeloma in patients presenting with osteoporosis was 75 (10 to 160). As a diagnostic test for multiple myeloma in patients with osteoporosis, M component in serum had a specificity of 95.0% and a positive predictive value of 17.6%. 122 blood electrophoreses were carried out for each case of multiple myeloma diagnosed. All patients with multiple myeloma had a history of fragility fractures. If lymphoma was included as a target condition, the specificity increased to 95.3% and the positive predictive value increased to 23.5%. Monoclonal gammopathy of undetermined significance was diagnosed in 13 (3.6%) participants with osteoporosis and in eight (2.0%) participants with normal bone mineral density or osteopenia. CONCLUSIONS:Patients presenting with osteoporosis should be tested for M component in serum, as 1 in 20 patients with newly diagnosed osteoporosis had multiple myeloma or monoclonal gammopathy of undetermined significance.
Authors: I Genvresse; C Lange; J Schanz; M Schweigert; H Harder; K Possinger; E Späth-Schwalbe Journal: Anticancer Drugs Date: 2001-04 Impact factor: 2.248
Authors: W Ben Sedrine; P Broers; J P Devogelaer; G Depresseux; J M Kaufman; S Goemaere; J Y Reginster Journal: Osteoporos Int Date: 2002-05 Impact factor: 4.507
Authors: Robert A Kyle; Morie A Gertz; Thomas E Witzig; John A Lust; Martha Q Lacy; Angela Dispenzieri; Rafael Fonseca; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew E Plevak; Terry M Therneau; Philip R Greipp Journal: Mayo Clin Proc Date: 2003-01 Impact factor: 7.616
Authors: Niels W C J van de Donk; Antonio Palumbo; Hans Erik Johnsen; Monika Engelhardt; Francesca Gay; Henrik Gregersen; Roman Hajek; Martina Kleber; Heinz Ludwig; Gareth Morgan; Pellegrino Musto; Torben Plesner; Orhan Sezer; Evangelos Terpos; Anders Waage; Sonja Zweegman; Hermann Einsele; Pieter Sonneveld; Henk M Lokhorst Journal: Haematologica Date: 2014-03-21 Impact factor: 9.941
Authors: Sigurdur Y Kristinsson; Min Tang; Ruth M Pfeiffer; Magnus Björkholm; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren Journal: Blood Date: 2010-07-07 Impact factor: 22.113